Plasmodium Vivax Infection
9
2
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.4% vs benchmark
22%
2 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (9)
Vivax Malaria Human Infection Studies in Thailand
Clinical Study to Assess Minimum Mosquito Bites for P. Vivax Infection in Thai Adults
A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 )
Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia
A Controlled Human Vivax Malaria Infection Study Through Inoculation of Infected Erythrocytes
Comparative Study of Thrombocytopenia in Plasmodium Vivax and Falciparum Malaria
Efficacy and Safety of Dihydroartemisinin-piperaquine (DHP) for the Treatment of Uncomplicated Malaria
Ethiopia Antimalarial in Vivo Efficacy Study 2012
Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity